Rate My Professor Aaron Sverdlov

Relocating to Newcastle in 2017, Sverdlov was appointed Associate Professor and Director of Heart Failure at the University of Newcastle, with promotion to Professor in December 2022. In partnership with Professor Doan Ngo, he established Australia's first bench-to-bedside cardio-oncology program, "Cancer and the Heart," integrating basic and clinical research on cancer therapy-related cardiotoxicity with an outpatient service at Calvary Mater Newcastle Hospital. His research interests include mechanisms of heart failure, particularly those linked to obesity and diabetes, mitochondrial and redox stress, novel biomarkers for heart disease detection, and cardio-oncology. Sverdlov has attracted over $18 million in competitive research funding, authored more than 120 peer-reviewed publications with an h-index of 32, and led the Australian Cardio-Oncology Roadmap and Research Priorities. Notable publications encompass "Oxidative Stress in Heart Failure" (2019, 2020), position statements on baseline cardiovascular risk assessment in cancer patients (2020), and studies on PARP inhibitors ameliorating doxorubicin-induced cardiotoxicity (2023). Awards include the Heart Foundation Future Leader Fellowship (2018-2022) for his heart failure research program, 2018 Ministerial Award for Rising Stars in Cardiovascular Research, NHMRC CJ Martin Fellowship, and American Heart Association Postdoctoral Fellowship. He holds fellowships from the Cardiac Society of Australia and New Zealand (FCSANZ), European Society of Cardiology (FESC), Heart Failure Association (FHFA), and American College of Cardiology (FACC).